The role of flavivirus-cross-reactive T lymphocytes in recovery from and pathogenesis of flavivirus infections is not known. In the present paper, we have defined a flavivirus-cross-reactive epitope recognized by two CD4 + CD8 cytotoxic T lymphocyte (CTL) clones, JK4 and JK43. The T cell clones were established from the peripheral blood T lymphocytes of a dengue-4-immune donor, using a limiting-dilution method with dengue-4 antigen. These two T cell clones were cross-reactive for dengue virus types 1, 2, 3 and 4, yellow fever virus and West Nile virus, and recognized NS3 protein. The smallest synthetic peptide recognized by these T cell clones was an identical 9 amino acid peptide which contains amino acids 146 to 154 (VIGLYGNGV) of dengue-4 NS3. HLA-DR15 was the restriction allele for recognition of this epitope by JK4 and JK43. JK4 and JK43 both used T cell receptor V~8, but JK4 used Vfl8 and JK43 used Vfl2. This result indicates that this epitope is recognized by two flavivirus-cross-reactive CD4 ÷ T cell clones which originated from different T cells in vivo.
Introduction
The Flaviviridae include at least 66 viruses which are transmitted by mosquitoes, ticks and unknown vectors (Monath, 1990) . About 40 % of the viruses which belong to the family Flaviviridae have been associated with human diseases. Dengue, yellow fever (YF) Japanese encephalitis, West Nile encephalitis and tick-borne encephalitiS" (TBE) are among the most important diseases caused by flavivirus infections (Monath, 1990) . The flavivirus genome consists of a single-stranded positive-sense RNA. The genome encodes three structural proteins: C (capsid), PrM (pre-membrane) and E (envelope) and seven non-structural proteins; NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5 (Chambers et al., 1990) .
T lymphocyte responses to flaviviruses have been analysed using human and murine lymphocytes. Memory T cells induced by infection with one serotype of dengue viruses included both dengue serotype-specific and serotype-cross-reactive populations (Rothman et al., 1989; Livingston et al., 1995) . Flavivirus-cross-reactive memory T cells were detected in some individuals * Author for correspondence. Fax + 1 508 856 4890.
immunized with experimental dengue vaccine (Green et al., 1993; Dharakul et al., 1994) . The presence of flavivirus-cross-reactive murine T cells was also reported using Murray Valley encephalitis and West Nile viruses (Lobigs et al., 1994) . These reports indicate that flavivirus-cross-reactive T cells are present in humans and mice.
Flavivirus-specific CD4 + T cells probably play an important role in immune responses to viruses by providing help for antibody production and for generation of CD8 + cytotoxic T lymphocytes (CTL). Some populations of CD4 + T cells also possess cytotoxic activity (Kurane et al., 1989a) . On the other hand, CD4 + T cells may contribute to the immunopathology that is observed in dengue haemorrhagic fever (Kurane & Ennis, 1992) . Although these assumptions must ultimately be based on epidemiological data, proteins which contain flavivirus-cross-reactive epitopes may be considered as components in experimental subunit vaccines against flaviviruses. These epitopes, however, should not be included in the subunit vaccines if flavivirus-crossreactive CD4 + CTL are shown to contribute to immunopathology. The present study defines the first flaviviruscross-reactive epitope recognized by human CD4 + CTL, and contributes to our understanding of flavivirus-crossreactive T cell responses.
Methods
Preparation of dengue virus antigens. Dengue virus type 1, Hawaii strain; type 2, New Guinea C strain; type 3, CH53489 strain; and type 4, 814669 strain; yellow fever virus (YFV) 17D strain; and West Nile virus (WNV), El01 strain were used. Dengue virus, YFV and WNV antigens were prepared from dengue virus-infected Veto cells as previously reported (Kurane et al., 1989b) . Veto cells were infected with viruses at an approximate m.o.i, of 1 p.f.u, per cell and cultured in MEM containing 2 % fetal calf serum (FCS). When 50 % of the monolayer had developed visible CPE, cells were removed with cell scrapers (Costar) washed three times with PBS at 4 °C, treated with 0.025% glutaraldehyde (Sigma) in PBS for 15rain at 4 °C, washed again three times with PBS, and resuspended in RPMI. The cells were then sonicated with a sonic dismembrater (Fisher Chemical) and centrifuged at 1500 g for 10 min. The supernatant fluid was collected and used as the virus antigen. Control antigen was prepared in a similar manner by using uninfected Vero cells. Antigen (3 mt) was obtained from fifteen 75 cm 2 flasks (Costar) of confluent Vero cells.
Establishment of dengue virus-specific T cell clones JK4 and JK43
using a limiting dilution method. Peripheral blood specimens were obtained from a donor twice, at 6 and 12 months after immunization with a live attenuated experimental dengue-3 (CH53489) candidate vaccine (Innis et al., 1988) . This donor had been immunized with YF vaccine 1 year before immunization with the dengue-3 candidate vaccine. The HLA type of the donor was DRBI*0103, DRBl*1501, DRB5*0101, DQB 1"0501, DQB 1"0602, DPA 1"01, DPB 1"0201, which is serologically defined as HLA-DR103, DR15, DR51, DQ5, DQ6, DPw2 (Bodmer et al., 1994) . HLA-DR and HLA-DQ typing was performed at American Red Cross. HLA-DP typing was performed by Dr Elaine Reed at the College of Physicians and Surgeons of Columbia University.
Peripheral blood mononuclear cells (PBMC) were separated from whole blood using the Ficoll-Hypaque density gradient centrifugation method. Dengue virus-specific T cell clones were established as previously reported (Kurane et al., 1991) . PBMC (4x 10 ~) were cultured for 7 days with dengue virus type 3 antigen at a final dilution of 1:30 in 0.2 ml of RPMI containing 10% human AB blood type serum in 96-well round-bottom plates. On day 7, blast cells were enriched by Ficoll-Hypaque density gradient centrifugation and were cultured at concentrations of 30, 10, 3, 1, and 0.3 cells per well with 1 x 105 gamma-irradiated (30 Gy) autologous PBMC in 0.2 ml of RPMI containing 10% human AB sera, 10% T cell growth factor (Cellular Products) and dengue virus type 3 antigen at a final dilution of 1:30 in 96-well round-bottom plates. On day 14, 0.I ml of medium was removed from each well and 1 x 105 gamma-irradiated autologous PBMC in 0.1 ml of fresh medium with human AB sera. T cell growth factor and dengue virus antigen were added to maintain the same final concentrations described above. On day 21, cells in wells demonstrating growth were transferred to 48-well flat bottom plates (Costar) and were further cultured with 106 gamma-irradiated autologous PBMC in 1 ml of RPMI containing 10 % human AB sera, 10 % T cell growth factor and dengue virus antigen at a dilution of 1 : 30. JK4 and JK43 were established from PBMC obtained at 6 and 12 months after immunization, respectively.
Recombinant vaccinia viruses.
The NS3 genes of dengue-2 (New Guinea C strain) and dengue-3 virus (H-87 strain) were amplified from genomic RNAs using the RT-PCR method with primers which contained unique BamHI and HindlII restriction sites. The resulting PCR product was ligated into the vaccinia transfer plasmid, pGK19, which contains both BamHI and HindIII restriction sites in its cloning cassette. Transfection of pGK 19 vectors into vaccinia virus (VV) strain WR-infected CV-1 cells results in recombination at the viral thymidine kinase gene locus. VV recombinants which contained the dengue NS3 gene were selected after growth in bromodeoyxuridine (20 mg/ml), plaque purified three times and grown to titres of 0.5 x l0 s to 5 x 108 p.f.u./ml on CV-1 cells. The presence of the NS3 gene in recombinant VV-infected CV-1 cells was demonstrated by SDS-PAGE and PCR.
Peptide synthesis. Peptides were synthesized according to the published a.a. sequence of the dengue-4 virus gene (Mackow et al., 1987) using the RAMPS Multiple Peptide Synthesis System (New England Nuclear) as previously reported (Takahashi et aL, 1991) . Peptides were also synthesized using the Symphony Peptide Synthesizer (Rainin Instruments) at the University of Massachusetts Peptide Core Facility. Amino acid analyses to verify amino acid composition of some peptides were performed by Dr Robert Carraway at the University of Massachusetts Medical Center Peptide Core Facility.
Preparation of lymphoblastoid cell lines.
A lymphoblastoid cell line (LCL) was established by infecting PBMC from the donor with Epstein-Barr virus obtained from an infected marmoset cell line (B95-8) that was purchased from the ATCC as previously reported (Kurane et al., 1991) CTL assays. 51Cr-labelled target cells (1 x 103) in 0.1 ml were added to each well in V-bottom microtitre plates (Linbro Chemical). Various concentrations of effector cells in 0" 1 ml of RPMI containing 10 % FCS was added to each well to give the described effector/target ratios. In cytotoxic assays using synthetic peptides, 1 x 10 a target cells in 0.1 ml of RPMI were incubated with the indicated concentration of peptide in 0.05 ml for 30 min and effector cells in 0.05 ml were then added to each well. After incubation at 37 °C for 4 h, the supernatant fluid was collected from each well and counted in an automatic gamma counter. The percentage specific 51Cr release was calculated by the following formula: 100 x (c.p.m. experimental release-c.p.m, spontaneous release)/(c.p.m, maximal release-c.p.m, spontaneous release). Peptide concentrations for half maximum lysis were calculated as previously reported .
Determination of T cell receptor ~ and fl usage.
Total cellular RNA was collected by the acid guanidinium-phenol~-chloroform (AGPC) method from 5 x 105 T cell clones (Chomczynski & Sacchi, 1987) . The RNA was treated with DNaseI and with RNAguard (Pharmacia) for protection. First-strand cDNA was synthesized from this RNA primed with random hexamers (Pharmacia) using Moloney murine leukaemia virus reverse transcriptase (Gibco BRL).
Twenty-five ~ and 26 fl T cell receptor (TCR) variable region-specific 5' PCR oligonucleotide primers and 3' PCR oligonucleotide primers specific for either the TCR ~ or fl constant region were synthesized at the DNA Synthesis Facility, University of Massachusetts Medical Center as previously reported (Okamoto et al., 1994) . To determine the amount of PCR products made per reaction, 3' primers were 32p end-labelled using T4 polynucleotide kinase (Promega) and purified by Chroma Spin-10 column (Clontech Laboratories). Primers with at least 1 x l0 s c.p.m, of radioactivity were used in each reaction. PCR was performed at least using the hot start method (Oksenberg et al., 1990) .
For TCRfl amplification we used 25 cycles of PCR at 95 °C for l min, 55 °C for 1 rain and 72 °C for 1 rain. For TCR e amplification, we used 30 cycles of PCR at 95 °C for 1 min, 46 °C for 1.5 min and 72 °C for 1 min (Okamoto et al., 1994) . Total reaction mixtures were electrophoresed in 5% polyacrylamide gels. The radioactivity of each amplified TCR fragment was examined by Betascope (Betagen) for 100 min.
PCR-amplified fragments were sequenced using the double-stranded DNA cycle sequencing system ((~ibco BRL) with 32P-labelled primers. Both strands were sequenced, and the sequencing reaction was primed with the 5'c~ or Vfl primers and 3' Cc~-specific (GGTACACGGCAG-GGTCAGGGTTC) or 3' C fl-specific (AGCGACCTCGGGTGGGA-ACAC) internal primer.
Results

Flavivirus-cross-reactive recognition by JK4 and JK43 clones
The establishment and characterization of the JK43 clone have been already reported (Kurane et al., 1991) .
The JK4 clone was established using the limiting-dilution method from PBMC obtained from the same donor 6 months after immunization with an experimental dengue-3 (CH53489) vaccine. JK4 and JK43 both had a CD3 + CD4 + CD8-phenotype.
These clones were examined for their virus specificities in cytotoxic assays (Table 1) . Both JK4 and JK43 lysed autologous LCL that had been pulsed with dengue-1 antigen (Ag), dengue-2 Ag, dengue-3 Ag, dengue 4-Ag, YFV Ag, or WNV Ag, but did not lyse LCL pulsed with control antigen. These results indicate that these two clones are flavivirus-cross-reactive.
Recognition of NS3 by JK4 and JK43
We had already reported that JK43 recognizes gelpurified NS3 protein (Kurane et al., 1991) . Recombinant vaccinia viruses which contain genes coding for dengue- 
Mapping of the epitope recognized by JK4 and JK43 using synthetic peptides
Using recombinant vaccinia viruses which expressed truncated versions of dengue-3 NS3, we first demonstrated that the epitope recognized by JK4 and JK43 was located between amino acids (a.a.) 134-214 on NS3 (data not presented). We then fine mapped the epitope using a series of ten overlapping ! 5 a.a. synthetic peptides which cover a.a. 134-214 of dengue-4 NS3 (Table 3 ). JK4 and JK43 recognized the peptide A25 which covers a.a. 140~155, but did not recognize the other peptides.
To delineate the smallest peptide recognized by these clones, we synthesized N and C terminus truncations of the peptide A29 and examined the recognition of these peptides at 2.5-2.5x 10 -7 lag/ml by JK4 and JK43 (Table 4) . Peptides A29c, A29d, A29e, A29f, and A29k sensitized target cells to lysis by JK4 and JK43. These results indicate that the 9 a.a. peptide A29k representing a.a. 146-154 with the a.a. sequence of VIGLYGNGV was the smallest recognition unit, since peptides smaller than this 9-mer peptide were not recognized by the T cell clones.
HLA DR15-restricted recognition of the epitope
To determine the HLA-restriction in recognition of the determined epitope, HLA-defined allogeneic target cells were pulsed with peptide A29 and were then used as target cells (Table 5) . Allogeneic target cells which share the HLA-DR15 (= DR2) allele were recognized in the presence of A29, but other allogeneic target cells which do not share HLA-DR15 (or DR2) were not recognized. * Target cells (1 × 103) were cultured with effector cells in the presence of peptides at 2.5 pg/ml for 5 h. Effector:target ratios were 10:1 for JK4 and 11 : 1 for JK43. ND, Not done. J In the presence of peptides at 2.5 × 10 -x ~tg/ml for JK4 and 2.5 × 10 2 ~tg/ml for JK43. ND, Not done. Therefore, recognition of the epitope by both JK4 and JK43 was HLA-DR15-restricted.
T cell receptor ~ and fl usage by JK4 and JK43
To examine whether JK4 and JK43 arose as separate T cell clones or whether they are two daughter clones which originated from the same T cell in vivo, we defined the usage of the T cell receptor V~ and Vfl by these clones, using the RT-PCR method. Although JK4 and JK43 both used V~8, JK4 used Vfl 8 and JK43 used Vfl2. We then sequenced 0~ and fl chains of JK4 and JK43 (Fig.  1) . The e and/q chains were all found to be in frame. Sequences in the complementarity determining region 3 (CDR3) of the e and fl chains were not the same between JK4 and JK43; however, there were similar amino acid sequences both in 0~ and fl chains. These results indicate that JK4 and JK43 originated from different T cells in vivo, and suggest that the recognition of the same peptide by JK4 and JK43 may be due to similar amino acid sequences in the CDR3 of the e and fl chains. 
Discussion
In this paper the epitope on NS3 recognized by two flavivirus-cross-reactive CD4 + CD8-T cell clones was mapped. Dengue-l, dengue-2, dengue-3, dengue-4 viruses, YFV and WNV were recognized by these two T cell clones. The minimum recognition unit of the epitope consists of 9 amino acids located between a.a. 146-154 on dengue-4 NS3 with the sequence VIGLYGNGV. Amino acid sequences in this region are well conserved among flaviviruses (Fig. 2) . Dengue-1 virus NS3 has two a.a. substitutions; I for V and V for I at the first and second a.a. positions of the minimum recognition unit, respectively (Fu et al., 1992) . Dengue-2 and dengue-3 virus NS3 both have the substitution V for I at the second a.a. position (Irie et al., 1989; Osatomi & Sumiyoshi, 1990) . YFV has one a.a. substitution, I for V at the ninth a.a. position (Rice et al., 1985) and WNV has the same a.a. sequence as dengue-4 in this region Wengler et al., 1985) . These limited, conserved amino acid substitutions are consistent with the observation that this epitope is recognized by flavivirus-cross-reactive T cell clones. Although other flaviviruses such as Japanese encephalitis virus, Murray Valley encephalitis virus and Kunjn virus antigens were not examined in the present experiments, Japanese encephalitis virus and Murray Valley encephalitis virus have the same single substitution; I for V at the first position (Lee et al., 1990; Sumiyoshi et al., 1987) and Kunjin virus contains no substitutions (Coia et al., 1988) .
The amino acid substitution, I for V at the first position is also present in dengue-1 virus; therefore, it is very likely that Japanese encephalitis virus, Murray Valley encephalitis virus and Kunjin virus would also be recognized by JK4 and JK43. Although JK4 and JK43 recognized the same 9-mer peptide in an HLA-DR15-restricted fashion, these two T cell clones utilized different T cell receptor Vp chains. It is generally accepted that V-(D)-J junctional regions (CDR3) of TCR ~ and p chains are most important in contacting peptides bound to MHC (Chien & Davis, 1993 portion are not completely conserved between JK4 and JK43, there are similar amino acid sequences in both the and fl chains. It is likely that recognition of the same peptide by JK4 and JK43 is due to these similar amino acid sequences in the CDR3.
The motif for HLA-DR2 (= 15) -binding peptides has been reported based on the peptides isolated from Epstein-Barr virus-transformed LCL which have HLA-DR genotype of DRBl*1501, DRB5*0101 (Chicz et al., 1993) . This HLA-DR genotype is the same as the genotype of our donor. The peptides were reported to have a motif of axxxxxxxxxb where ' a' is I, L or V and 'b' is H, K or R, and 7 of 10 isolated peptides had core sequences consistant with the motif. The smallest peptide (A29k) recognized by JK4 and JK43 has V at the first position and I at the second position, but does not have H, K or R at eleventh position because of it being a 9 a.a. peptide. Interestingly, two peptides which were isolated from LCL with HLA-DR2 and were determined to originate from HLA-DQ~ chain did not have core sequence of DR2 binding motif but had VI sequence at the 3rd and 4th position (Chicz et al., 1993) . It is, therefore, possible that V at first position or I at second position may be important for binding of the peptide A28k to HLA-DR15.
The role of flavivirus-cross-reactive immune responses in the recovery from or in the pathogenesis of flavivirus infections such as dengue haemorrhagic fever (DHF) is not known. Some vaccinees who did not have detectable levels of antibody to flaviviruses before immunization developed memory T cells which were cross-reactive for dengue-l, -3 and -4 viruses, YFV and WNV after immunization with experimental dengue-2 vaccine (Dharakul et al., 1994) . As reported in the present paper, flavivirus-cross-reactive clones have been established from the T cells of a donor who was immunized with an experimental dengue-3 vaccine. Thus, it is possible that these flavivirus-cross-reactive T cells play an important role in the prevention of or recovery from flavivirus infection, although there is no solid epidemiological evidence that immunity to one flavivirus provides protection against infection by other flaviviruses. If this is the case, the present study provides information about the flavivirus-cross-reactive epitopes to be included in putative subunit vaccine against multiple fiaviviruses. It is important to elucidate flavivirus-cross-reactive T cell responses in humans further in order to understand their role in flavivirus infections.
Epidemiological studies in Thailand and Cuba have indicated that there is a higher incidence of dengue haemorrhagic fever (DHF) after a secondary infection with a dengue serotype different from the one that induced the primary dengue infection. It has been speculated that DHF is caused by immunopathological mechanisms due to dengue serotype-cross-reactive immune responses (Halstead, 1988; Kurane & Ennis, 1992) . It is important to examine epidemiologically whether flavivirus-cross-reactive immune responses may also contribute to the pathogenesis of DHF, since there are geographical regions where dengue viruses and other flaviviruses such as Japanese encephalitis virus are both preva|ent (Innis et al., 1989) . The presence of fiaviviruscross-reactive T cell and antibody epitopes also suggests that it may be possible to develop a vaccine which is effective against multiple flaviviruses.
